Atopic eczema (AE) is a chronic disease with flares and remissions. Long-term control of AE flares has been identified as a core outcome domain for AE trials. However, it is unclear how flares should be defined and measured.
To validate two concepts of AE flares based on daily reports of topical medication use: (i) escalation of treatment and (ii) days of topical anti-inflammatory medication use (topical corticosteroids and/or calcineurin inhibitors).
Data from two published AE studies (studies A (n=336) and B (n=60)) were analysed separately. Validity and feasibility of flare definitions were assessed using daily global bother (scale 0 to 10) as the reference standard. Intra-class correlations were reported for continuous variables, and odds ratios and area under the receiver operator characteristic (ROC) curve for binary outcome measures.
Good agreement was found between both AE flare definitions and change in global bother: area under the ROC curve for treatment escalation of 0.70 and 0.73 in studies A and B respectively, and area under the ROC curve of 0.69 for topical anti-inflammatory medication use (Study A only). Significant positive relationships were found between validated severity scales (POEM, SASSAD, TIS) and the duration of AE flares occurring in the previous week – POEM and SASSAD rose by half a point for each unit increase in number of days in flare. Smaller increases were observed on the TIS scale. Completeness of daily diaries was 95% for Study A and 60% for Study B over 16 weeks).
Both definitions were good proxy indicators of AE flares. We found no evidence that ‘escalation of treatment’ was a better measure of AE flares than ‘use of topical anti-inflammatory medications’. Capturing disease flares in AE trials through daily recording of medication use is feasible and appears to be a good indicator of long-term control.
Citation: Thomas KS, Stuart B, O’Leary CJ, Schmitt J, Paul C, Williams HC, et al. (2015) Validation of Treatment Escalation as a Definition of Atopic Eczema Flares. PLoS ONE 10(4): e0124770. https://doi.org/10.1371/journal.pone.0124770
Academic Editor: Jian-Xin Gao, Shanghai Jiao Tong University School of Medicine, CHINA
Received: November 7, 2014; Accepted: March 12, 2015; Published: April 21, 2015
Copyright: © 2015 Thomas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: Data included in this manuscript is not able to be included in a public repository due to ethical restrictions. Requests for access to the data should be made to Professor Kim Thomas (firstname.lastname@example.org).
Funding: This study uses data that was first collected in a national trial funded by the National Institute for Health Research, Health Technology Assessment (NIHR HTA) Programme, project number HTA 05/16 (http://www.journalslibrary.nihr.ac.uk/hta/volume-15/issue-8), and through a study funded through an NIHR Clinician Scientist Fellowship awarded to Doctor Langan, grant number: NIHR/CS/010/014. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Atopic eczema (AE) is a chronic relapsing skin condition that is characterised by periods of disease flare, followed by periods of relatively well-controlled disease . In this regard it is similar to many chronic inflammatory conditions such as asthma or rheumatoid arthritis, where disease flare may be captured by escalation of treatment or symptoms [2–4]. For chronic conditions, assessment of disease control over time in clinical studies can be particularly challenging [5,6]. The concept of AE flares is one way of capturing disease chronicity, and may be a useful outcome for long-term, comparative effectiveness trials.
In recent years there has been growing interest in secondary prevention strategies for the management of AE, and prevention of flares has been advocated as a useful outcome measure in this context. The most extensive use of flare definitions in the AE literature is in relation to proactive treatment with topical corticosteroids or topical calcineurin inhibitors .
Two systematic reviews on how best to capture AE flares have shown that there is considerable variation in the definitions used to measure AE flares in clinical trials [5,8]. Many flare definitions rely on a physician’s assessment of the flare rather than assessment by patients, which are potentially more relevant but challenging to assess in long-term studies.
A review published in 2006 proposed a provisional definition of AE flares based on the need to escalate AE treatment in response to worsening of disease . This definition assumed that escalation of treatment (or rescue therapy) was a good indicator of disease flares as it was a behavioural response to worsening of disease from the patient’s perspective. The proposed definition has now been used in several clinical studies; two of which have been used to inform this paper due to the availability of the study data[9,10] In this paper we describe and analyse our preliminary experiences of using both ‘escalation of treatment’ and ‘days of topical anti-inflammatory medication use’ as measures of AE flares. The results will be used to inform the Harmonising Outcome Measures for Eczema (HOME) initiative with regards to the most appropriate outcome measures to be used for the measurement of long-term control in clinical trials. The HOME initiative is an international collaboration working together to agree on a core set of outcome measures for use in all future AE clinical trials [11–13].
The specific aims of this study were: i) to assess the feasibility and validity of capturing AE flares from daily diary data in long-term studies; ii) to inform the “HOME Long-Term Control Working Group” in its consideration of the most appropriate way of capturing long-term disease control as part of a core outcome set for AE. Two primary hypotheses were tested: i) that days of escalation of treatment was a good indicator of overall disease control; ii) that escalation of treatment was a better indicator of long-term control than days of topical anti-inflammatory medication use (topical corticosteroids and/or topical calcineurin inhibitors).
Ethics approval was not required for the study as analysis was based on existing datasets from previously conducted studies.
Data available from original studies
Data from two UK-based studies including children with moderate to severe AE have been used to inform this analysis.).
Study A: Softened Water Eczema Trial (SWET) .
A 4 month, observer blind, randomised controlled trial involving 336 children with moderate to severe AE. Participants received normal care plus an ion-exchange water softener, or normal care alone. The primary outcome was AE severity, as assessed by blinded research nurses, using an objective severity scale . Children, or their parent / guardian, completed paper diaries daily throughout the study (older children completed the diaries for themselves as appropriate).
Study B: Observational study to identify flare triggers .
A 6 month prospective cohort study involving 60 children with moderate to severe AE. The objective of the study was to assess the association between environmental exposures and disease flares in AE. Children or their parents completed daily electronic diaries capturing disease severity and environmental exposures. The primary outcome was a global “bother” score on a scale of 0–10 (where 0 represented no bother and 10 the most bother that they could imagine). This simple, patient-centred outcome was previously used in the development of a well validated AE severity scale . In long-term studies of this kind, use of a simple scale minimises the daily burden on responders.
For both studies, normal AE treatment and ‘escalation therapy' were defined on entry into the study, on an individual patient basis, following discussion with the patients and/or their parents or guardians (Fig 1). The decision to escalate treatment as a result of an exacerbation of AE was assessed daily as a binary yes / no response using either paper , or electronic  diaries. Electronic diaries allowed daily information to be entered up to midnight each day. Other outcomes that were collected on either a weekly or a monthly basis included the Patient Oriented Outcome Measure—POEM , Three Item Severity scale—TIS , and the Six Signs, Six Areas Atopic Dermatitis scale—SASSAD  in study A only.
Key research questions
The HOME initiative has adopted the Outcome Measures in Rheumatology (OMERACT) filter for the assessment of potential outcome measure for inclusion in the recommended core outcome set [12,18]. The OMERACT filter requires the assessment of three key features of potential outcome instruments: “truth, discrimination, and feasibility”.
The current study sought to evaluate our two definitions of AE flares (days when treatment was escalated and days of topical anti-inflammatory medication use), against the OMERACT filter (for truth and feasibility), in order to establish whether or not these outcomes could be useful in capturing long-term control of AE flares in future clinical trials. The following research questions were explored.
- Truth: what is the flare definition measuring?
- 1). What proportion of study days report an AE flare using the two flare definitions?
- 2). How does the number of days in flare (as defined by the two flare definitions) relate to increases in self-reported AE ‘global bother’?
- 3). How does the number of days in flare (as defined by the two flare definitions) correlate with other validated AE severity scales? [14–16]
- 4). Is ‘escalation of treatment’ a better indicator of global bother scores than ‘topical anti-inflammatory medication’?
- Feasibility: is the scale feasible and acceptable for use in a variety of settings?
- 5). How acceptable and easy to use is the concept of ‘escalation of treatment’ for participants and investigators?
- 6). How complete are the two datasets, and did the use of paper diaries compared to electronic diaries influence the completeness of the data?
The sample size for this study was based on availability of data from the previous studies and no formal sample size estimation was conducted. Nevertheless, a sample size of >100 participants per analysis has been recommended as sufficient for validation studies .
The two datasets are reported descriptively, and have been analysed separately in order to explore the consistency of our findings across different datasets.
Two aspects of disease control were collected on a daily basis for 16 weeks in both studies: i) “How much bother has the AE caused today?”, and ii) “Has an escalation in treatment been required?” For Study A, use of topical anti-inflammatory medications (corticosteroids and/or topical calcineurin inhibitors) was also captured daily.
These daily data were used to calculate i) average ‘global bother’ scores, ii) average number of days when treatment was escalated, and iii) average number of days of topical anti-inflammatory use. The average number of days in flare captured consecutive and non-consecutive days of flare in the same way. Thus an AE flare lasting a week was captured as seven days of flare in the same way as seven non-consecutive days of AE flare.
For analyses summarising the number of weeks in flare, a week was defined as being ‘in flare’ if a participant stepped up treatment, or applied topical anti-inflammatories, at least once in that week. When comparing the number of days in flare with existing validated scales, the number of days when treatment was escalated or anti-inflammatory medication was applied in the previous week was used.
Correlations between scales are reported using the intra-class correlation (ICC) for continuous outcome measures, and odds ratios (OR) with 95% CIs and area under the receiver operator characteristic curve (ROC) for binary outcome measures.
It was hypothesised that those with a higher global bother score on a given day would be more likely to escalate treatment, and that escalation of treatment would capture disease control better than use of topical anti-inflammatory medication.
In any week if a participant was missing data on whether or not they escalated treatment or used anti-inflammatory medication, we assumed that they did not do so. Missing values on any other key variables were treated as missing. Given the repeated measures nature of the study and the fact that many participants were missing at least one observation over the 16 week study period, the data were analysed using mixed models in Stata version 12.1 (e.g. xtlogit). This allows participants who have missing data to contribute information for any periods for which they have data.
Guidelines on essential features of studies to assess the psychometric properties of outcome scales have been followed in designing this study .
Overall, 396 participants contributed to the analyses (n = 336 for Study A and n = 60 for Study B). Baseline characteristics of included participants are summarised (Table 1).
Truth: what are the flare definitions measuring?
Research question 1: What proportion of study days report an AE flare using the two flare definitions?
Summary data for all outcomes are summarised in Table 2.
Throughout the 16 week study period, participants reported a flare based on escalation of treatment on 21% of the study days (23/112 days) for both Study A and Study B. This compares with 44% of days (49/112 days) when anti-inflammatory medications were used (data from Study A only). The proportion of days in flare by disease severity are summarised (Fig 2).
Research question 2: How does the number of days in flare relate to increases in self-reported ‘global bother’?
Overall there was a fairly good level of agreement between the global bother score and the measure of flare based on escalation of treatment, with an area under the ROC curve (sometimes called the “c-statistic”) of 0.70 (95% CI 0.69, 0.71) for Study A and 0.73 (95% CI 0.71, 0.74) for Study B. There was a similar level of agreement between the global bother score and days of topical anti-inflammatory medication use in study A, with a c-statistic of 0.69 (95% CI 0.67, 0.69).
To assess the impact of incremental changes in the global bother score, we compared the odds of escalating treatment and the odds of using topical anti-inflammatory medication by daily bother score (Table 3). The mean overall global bother score for Study A was 4.45 (SD 2.35), whilst for Study B the mean was 3.46 (SD 2.70), so a global bother score of four was chosen as the baseline for comparison. In both datasets, participants with global bother scores of less than four were significantly less likely to escalate treatment than those with the average score for each study of 4 (p<0.0001 for all comparisons), whilst those with a global bother score of more than four were significantly more likely to escalate treatment than those with the average score. Similar results were found for topical anti-inflammatory medication use (p<0.0001 for all comparisons) (Table 3).
When data are examined according to a change in bother score relative to the previous day, participants were twice as likely to escalate treatment or to use topical anti-inflammatory medication if they experienced a one point worsening of the global bother score, or four times more likely to escalate treatment or to use topical anti-inflammatory medication if the global bother score worsened by two points or more compared to those who did not have any change in their bother score or who improved. All results were statistically significant at p<0.0001 (Table 4).
Research question 3: How does the number of days in flare correlate with other validated AE severity scales?
There was a significant relationship between increasing severity as demonstrated using validated AE severity scales and the number of days when escalation of treatment was required in the preceding week. For POEM and SASSAD AE severity scales, both outcomes rose by about half a point for each unit increase in the number of days with a flare. For TIS, a small positive relationship was observed, but this was not significant (Table 5). The relationship between the AE severity scales and the use of topical anti-inflammatory medication was similar with POEM and SASSAD, increasing by about half a point for each 1-day increase in the number of days on which topical anti-inflammatory medication was used in a week. There was also a small, statistically significant increases in the TIS (Table 5).
Research question 4: Is ‘escalation of treatment’ a better indicator of global bother scores than ‘topical anti-inflammatory medication’?
It is likely that a flare definition based on use of anti-inflammatory medication may have overestimated the number of AE flares (44% of study days were classed as flare), and that this definition is potentially more likely to be influenced by variations in adherence to topical medications. Nevertheless, contrary to our original hypothesis, days of topical anti-inflammatory medication use performed just as well as days when treatment was escalated for all analyses, hence could be considered as an alternative to the escalation of treatment definition of AE flares.
Feasibility: is the scale acceptable for use in a variety of settings?
Informal feedback from study participants was that completing the diaries on a daily basis was acceptable and relevant to the management of their AE. In some cases participants valued the use of a tool that allowed AE severity to be tracked over time. Since the need to escalate treatment in response to an AE flare was individualised to each participant, this was discussed face-to-face with participants (or their parent /guardian) on entry into each study. The types of treatment used as interventions to control AE flares varied, from use of mild topical corticosteroids through to the use of wet wrap dressings. For participants using systemic therapy, the need for additional topical treatments in addition to the systemic therapy was used to define worsening of the eczema, as systemic therapy is unlikely to be changed on a daily basis in response to changing disease activity.
Potential problems in using daily diaries to collect long-term disease control data included: the burden of data collection for participants (and resulting data management for the research team); potential confusion for participants about what is classified as “treatment escalation” if their treatment regimen changes during the period of the study; potential confusion over dates of data entry; and the restrictive data entry window for the electronic diaries that prevented data capture the following day.
The amount of missing data varied between the two studies. Data collection was more complete for Study A than Study B. For Study A, 95% of all possible daily data points were completed at 3-months and 94% of the possible daily data points were completed at 4-months, whereas for Study B, the number of complete data points at 3-months was 63% and at 4-months was 60%. The lower completion rates for Study B likely reflects the use of electronic diaries that prohibited completion after midnight each night.
The flare definition based on the need for escalation of therapy, first proposed by our group in 2006, has been explored in two clinical studies. Lessons have been learned in relation to the validity and feasibility of escalation of therapy as an indicator of flares in an applied setting. This study also provided an opportunity to evaluate a second measure of long-term control, namely daily use of topical anti-inflammatory medication.
In general our behavioural definition of AE flares, based on escalation of AE treatment, performed relatively well. The scale had face validity, in that the need to escalate treatment was intuitively understood by participants and investigators, and good construct validity, as the proportion of days in flare correlated positively with changes in ‘bother scores’ and validated severity scales (SASSAD and POEM). The difficulty of interpreting traditional AE severity scores has been highlighted by others , and having an outcome that is based on the number of days a patient has experienced an AE flare is a concept that is easily understood by both clinicians and patients.
Escalation of therapy or use of topical anti-inflammatory medication as a measure of AE flares?
Contrary to our original hypothesis that escalation of therapy was a better measure of disease control than use of topical anti-inflammatory medications, the current study found that both scales performed well (although data on daily anti-inflammatory medication use was only available in one of the two datasets). If replicated in other settings, this finding is important, as it is potentially easier to collect the number of days when anti-inflammatory medication has been used, than it is to collect the number of days when therapy was escalated (as the latter requires individualised assessment for each participant, and may change during the course of a long-term study). Simply capturing days of anti-inflammatory medication use will also capture those using proactive treatment for the prevention (rather than treatment) of flares, and it is possible that such practice was less prevalent during the period when these two studies took place.
Some issues also remain with regards to the reliability and repeatability of the self-reported escalation of treatment, as it is not possible to establish whether participants in these studies interpreted the need to escalate treatment consistently throughout the study period. It is also possible that using an individualised approach to flare definition could make it more difficult to compare different studies and to pool data in meta-analyses. In this regard, asking participants to record whether or not they have applied topical anti-inflammatory medication on a daily (or weekly) basis, can also be challenging. Participants who are responding well to a given intervention may reduce the potency of their topical medication without reducing the total amount used; making it difficult to interpret data based solely on days of use. Variation in practice may also mean that some patients will have been advised to treat each flare episode aggressively, whilst others may not, with fear of side effects from topical corticosteroids affecting adherence to treatment independent of disease activity [21,22]. As an alternative to daily data collection of medication use, some AE trials have measured the total amount of topical medication used, either by weighing returned tubes or by recording the number of prescriptions issued. Further work would be helpful to establish the validity and feasibility of this approach, and to evaluate the accuracy of self-reported medication-use data through comparison with electronic monitors .
Although the included studies were of 4- and 6-months’ duration, the amount of missing data reported was surprisingly low, and patients appeared willing to complete the daily dairies for relatively lengthy periods of time. Nevertheless, the discrepancy between the number of missing data items in paper diaries compared to electronic diaries would suggest that some data may have been entered retrospectively in the paper diaries. This could be acceptable if the entries were completed within a couple of days of the flare, and it is likely that the electronic diaries were unduly strict in defining the time window for each day. With the increasing availability of, Smartphone technologies and, it is likely that a future application could be developed to address these issues.
Relevance to other literature
Others have adopted similar behavioural definition of AE flares, based on the need to escalate treatment as a result of worsening disease [24–29], although the exact wording of these definitions has not been formally validated.
For other allergic diseases there is growing awareness of the need for core outcome sets. In the field of asthma, disease exacerbations have been identified as a core domain for inclusion in all future asthma trials . It has been proposed that these should be captured using behavioural markers of exacerbation, such as use of systemic steroids, hospital admissions, emergency department visits and death . Whilst AE flares are rarely of sufficient severity to warrant hospital admission or emergency care, this definition of an exacerbation shares the same concept of being a behavioural response to a worsening of the disease. For some AE studies, escalation of treatment could reasonably be interpreted as a need to seek health care advice, but in most cases accessing of health services is unlikely to be sensitive to change, and is probably not ideal as a single measure of flare.
Strengths and weaknesses of this study
Strengths of this study are that daily data on escalation of therapy and topical medication use were available from two independent studies. The two datasets were examined and reported separately, and the associations identified in Study A were replicated in Study B. However, as the data from these studies was originally collected for another purpose, our analyses were determined by data availability. For this reason, the suggestion that topical medication use on a daily basis may be a useful indicator of disease control was only evaluated in Study A, and further work to validate this finding is required.
It is also the case that both studies recruited patients with moderate to severe AE, and it will be important to evaluate the relevance of the proposed outcome measures in patients with milder disease. Nevertheless, these studies tested two different methods of data collection (paper versus electronic data capture), and evaluated outcomes in long-term studies; thus providing information as to the feasibility of this approach in future long-term trials.
It is not yet clear whether the results seen in this study are applicable to the types of patients seen in primary care, who are likely to have much milder AE and may be less willing to use topical corticosteroids due to fear of side-effects. As the flare definition based on escalation of treatment, is specified on an individual basis at the start of the study, this outcome could, in theory, be used across all severity groups.
Implications for research and clinical practice
This is the first study to have formally validated a measure of disease exacerbations or flares in AE. By concentrating on the number of days in flare, rather than the number of discreet flare episodes, we have not formally defined what constitutes the end of one flare episode and the start of another. This distinction may be important for studies that are assessing the duration of AE flares and the number of flare episodes over a period of time.
Capturing disease flares in long-term AE studies is potentially burdensome for patients and researchers and remains a challenge. Nevertheless, our experiences from two large-scale, prospective studies would suggest that escalation of treatment and use of topical anti-inflammatory medications can be good indicators of long-term disease control.
We would like to thank the collaborators and patients who contributed to the development and delivery of the two studies described in this paper. For full details of contributors to these studies, please see the original published study reports [9,10]. Thanks also to Natasha Rogers for her support as author’s editor in finalising this manuscript.
This study has been conducted in support of the Harmonizing Outcome Measure for Eczema (HOME) initiative, and we thank HOME members who have helped to inform the development and concepts described in this study. For full details of the HOME initiative see: www.homeforeczema.org
OCRID ID: 0000-0001-7785-7465
Conceived and designed the experiments: KST BS COL JS CP HCW SL. Performed the experiments: KST COL SL HCW. Analyzed the data: BS COL. Wrote the paper: KST BS COL JS CP HCW SL.
- 1. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, et al. (1994) The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 131: 383–396. pmid:7918015
- 2. Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr, et al. (2012) Asthma outcomes: exacerbations. J Allergy Clin Immunol 129: S34–48. pmid:22386508
- 3. Bingham CO 3rd, Pohl C, Woodworth TG, Hewlett SE, May JE, et al. (2009) Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 36: 2335–2341. pmid:19684147
- 4. Bartlett SJ, Hewlett S, Bingham CO, Woodworth TG, Alten R, et al. (2012) Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Annals of the Rheumatic Diseases.
- 5. Langan SM, Schmitt J, Williams HC, Smith S, Thomas KS (2014) How are eczema 'flares' defined? A systematic review and recommendation for future studies. Br J Dermatol 170: 548–556. pmid:24266741
- 6. Cloutier MM, Schatz M, Castro M, Clark N, Kelly HW, et al. (2012) Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol 129: S24–33. pmid:22386507
- 7. Schmitt J, von Kobyletzki L, Svensson Å, Apfelbacher C (2011) Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology 164: 415–428. pmid:20819086
- 8. Langan SM, Thomas KS, Williams HC (2006) What is meant by a "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol 142: 1190–1196. pmid:16983006
- 9. Langan SM, Silcocks P, Williams HC (2009) What causes flares of eczema in children? Br J Dermatol 161: 640–646. pmid:19656150
- 10. Thomas KS, Dean T, O'Leary C, Sach TH, Koller K, et al. (2011) A randomised controlled trial of ion-exchange water softeners for the treatment of eczema in children. PLoS Med 8: e1000395. pmid:21358807
- 11. HOME initiative Harmonising Outcome Measures for Eczema.
- 12. Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, et al. (2012) Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 67: 1111–1117. pmid:22844983
- 13. Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, et al. (2014) Report from the Third International Consensus Meeting to Harmonise Core Outcome Measures for Atopic Eczema / Dermatitis Clinical Trials (HOME). Br J Dermatol.
- 14. Berth-Jones J (1996) Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 135: 25–30. pmid:8881901
- 15. Charman CR, Venn AJ, Williams HC (2004) The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 140: 1513–1519. pmid:15611432
- 16. Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP (1999) Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 79: 356–359. pmid:10494710
- 17. Boers M, Brooks P, Strand CV, Tugwell P (1998) The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 25: 198–199. pmid:9489805
- 18. Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, et al. (2014) The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology. J Invest Dermatol.
- 19. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, et al. (2012) Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 21: 651–657. pmid:21732199
- 20. Charman CR, Venn AJ, Ravenscroft JC, Williams HC (2013) Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 169: 1326–1332. pmid:24024631
- 21. Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, et al. (2013) Factors Associated with Steroid Phobia in Caregivers of Children with Atopic Dermatitis. Pediatric Dermatology 30: 29–35. pmid:22747965
- 22. Charman C, Williams H (2003) The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clinics in Dermatology 21: 193–200. pmid:12781437
- 23. Greenlaw SM, Yentzer BA, O'Neill JL, Balkrishnan R, Feldman SR (2010) Assessing adherence to dermatology treatments: a review of self-report and electronic measures. Skin Res Technol 16: 253–258. pmid:20456106
- 24. Zaki I, Emerson R, Allen BR (1996) Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 135 Suppl 48: 21–24. pmid:8881900
- 25. Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, et al. (2009) Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 23: 1267–1272. pmid:19508310
- 26. Sigurgeirsson B, Ho V, Ferrandiz C, Andriano K, Grinienko A, et al. (2008) Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol 22: 1290–1301. pmid:18624866
- 27. Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, et al. (2008) Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 158: 801–807. pmid:18284403
- 28. Boguniewicz M, Zeichner JA, Eichenfield LF, Hebert AA, Jarratt M, et al. (2008) MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr 152: 854–859. pmid:18492531
- 29. Becker D, Langer E, Seemann M, Seemann G, Fell I, et al. (2011) Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis. PLoS One 6: e20566. pmid:21687679